Placebo Clinical Trial
Official title:
Pexacerfont for Reduction of Stress-Induced Food Craving and Eating in Humans
Background:
- Stress can cause people to give in to temptations to eat less healthily. People who are on
weight loss diets often have problems sticking to their diets when they are stressed. Some
tests have shown that the drug pexacerfont can help reduce stress-related seeking of
high-calorie foods. However, it has not been tested on reducing food craving. Researchers
want to test pexacerfont on people who are on diets to see if it can reduce stress-related
food cravings.
Objectives:
- To see if pexacerfont can help reduce stress-induced food cravings.
Eligibility:
- Individuals between 21 and 65 years of age who are on a diet to control their weight.
Design:
- Participants will be screened with a physical exam and medical history. This study
requires seven visits over about 35 days.
- Participants will take either pexacerfont or placebo pills during the study. They will
have three pills every morning. They will record video of themselves taking the pills
every day.
- Every evening, participants will fill out a questionnaire. It will ask questions about
feelings and behaviors related to eating and food craving.
- Participants will have regular study visits while taking the pills. The visits will
involve questions about stressful situations and food cravings. One visit will involve
a mildly stressful math test, followed by tasting of different foods. This test will
look at whether pexacerfont can affect food preferences. Participants will provide
blood and saliva samples as directed at these study visits.
- Participants will have follow-up phone calls 1, 3, and 6 months after the end of the
study.
Objective: To evaluate pexacerfont, an orally available, brain-penetrant selective CRF1
antagonist, for its ability to modulate food craving and consumption in chronic unsuccessful
dieters.
Study population: We will collect evaluable data from up to 90 restrained eaters
(individuals who indicate a history of chronic yo-yo dieting by scoring 15 or higher on the
Dietary Restraint Scale). To ensure that all participants have some degree of preoccupation
with food, an additional inclusion criterion will be endorsement of the Restraint Scale item
Do you give too much time and thought to food? Apart from their preoccupation with food,
participants will be healthy. They can be either normal-weight or overweight (Body Mass
Index (BMI) > 22kg/m2); this will be stratified across dose groups.
Frank eating disorders will be exclusionary.
Design: This will be a randomized, double-blind, between-groups study with two groups.
Participants will be stabilized on either pexacerfont or placebo for 28 days (300 mg/day
loading dose for 7 days, followed by 100 mg/day maintenance dose for 21 days). On day 15,
they will undergo a math-test stressor and have stress-induced food consumption and craving
assessed in a bogus taste test and on visual-analog scales. During three subsequent visits
between days 16 and 28, they will be exposed to three personalized imagery-induction
scripts-one stress-related, one food-related, and one neutral/relaxing. Food craving and
food consumption will be assessed on those visits as well.
Outcome measures: The primary outcome measure is stress-induced eating after the math-test
stressor. Other outcome measures will include spontaneous food consumption after the other
stressors, subjective ratings of stress, mood, and food craving, autonomic responses
(galvanic skin response (GSR), heart rate, and blood pressure), and endocrine responses
(salivary cortisol, salivary alpha-amylase, and serum cortisol).
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04852315 -
Acute Caffeine Ingestion on Futsal Performance
|
N/A | |
Completed |
NCT05427409 -
Ingestion of Beta-alanine Effects in Well-trained Tennis Players
|
N/A | |
Completed |
NCT05425563 -
Effects of Expectations on Negative Affect, Perceived Cognitive Effort, and Pain
|
N/A | |
Recruiting |
NCT05007561 -
Understanding How Opioids Affect the Experiential and Neural Signatures of Social Experiences
|
Early Phase 1 | |
Recruiting |
NCT04851301 -
Neural Mechanisms of Immersive Virtual Reality in Chronic Pain
|
Phase 1/Phase 2 | |
Recruiting |
NCT03897998 -
Neural Correlates of Hypoalgesia Driven by Observation
|
Phase 2 | |
Completed |
NCT04359147 -
The Role of Stress Neuromodulators in Decision Making Under Risk and Selective Attention to Threat
|
N/A | |
Recruiting |
NCT05145764 -
Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl
|
Phase 2 | |
Completed |
NCT01167478 -
Neurophysiological Reserve With Caffeine Manipulation
|
N/A | |
Completed |
NCT05337527 -
Neuromuscular Responses to Acute Beetroot Ingestion in Women Older Adults
|
N/A | |
Completed |
NCT04361968 -
Combining Animal-assisted Intervention and Placebo-induced Analgesia
|
N/A | |
Completed |
NCT03754062 -
Pharmacological Modulation of Belief Salience
|
Phase 1 | |
Not yet recruiting |
NCT04317157 -
Placebo Effects Investigated by Different Experimental Designs
|
N/A | |
Completed |
NCT01361633 -
The Cognitive Enhancing Effects of D-Cycloserine Among Non-Demented Elderly
|
Phase 2 | |
Completed |
NCT05209126 -
Impact of Beetroot Juice Ingestion on Female Rugby Performance
|
N/A | |
Completed |
NCT05521347 -
Caffeine Supplementation Improves the Cognitive Abilities and Shooting Performance of Trained E-sports Players
|
N/A | |
Completed |
NCT04975360 -
Delayed-release Bedtime Caffeine and Sleep Inertia Symptoms Immediately Upon Awakening
|
N/A | |
Completed |
NCT04671043 -
Caffeine Ingestion to Counter the Exercise-mediated Fall in Glycaemia in Type 1 Diabetes
|
N/A | |
Completed |
NCT01011465 -
The Biology of Resilience
|
N/A | |
Completed |
NCT05805540 -
Effects on CK, RPE, VAS Scale and Physical Performance of Three Recovery Methods in Elite Basketball Players
|
N/A |